Bronchoprotective and bronchodilator activity of anaritide (human atrial natriuretic factor [102-126]) infusion in the anesthetized guinea pig

Pulm Pharmacol. 1988;1(3):119-23. doi: 10.1016/s0952-0600(88)80009-7.

Abstract

The present study examined the bronchoprotective and bronchodilator efficacy of infused human atrial natriuretic factor [102-126] (Anaritide) in the guinea pig. Anesthetized and paralyzed male guinea pigs, ventilated via a tracheal cannula, were placed in a plethysmograph for measurement of agonist-induced changes in pulmonary mechanics. Reductions in dynamic compliance of the lung and airway conductance were produced either by 3 to 7 tidal volume breaths of leukotriene D4 (0.125 micrograms/ml) delivered through an ultrasonic nebulizer or by intravenous histamine (2.8 +/- 0.2 micrograms/kg). Infusion of Anaritide (1 microgram/kg/min), before evoking bronchoconstriction with either LTD4 or histamine, produced a significant protection against bronchoconstriction produced by aerosol LTD4, but not against histamine-induced bronchoconstriction of similar magnitude. In other experiments, Anaritide infusion (0.5-2 micrograms/kg/min) also rapidly reversed a stable LTD4-induced decrease in airway conductance, but did not produce a similar reversal of the decrease in dynamic compliance. The data provide evidence that intravenous Anaritide exerts both bronchoprotective and bronchodilator effects against LTD4-induced bronchospasm.

MeSH terms

  • Animals
  • Atrial Natriuretic Factor / pharmacology*
  • Bronchi / drug effects*
  • Bronchoconstriction / drug effects
  • Bronchodilator Agents / pharmacology*
  • Guinea Pigs
  • In Vitro Techniques
  • Male
  • Peptide Fragments / pharmacology*
  • SRS-A / antagonists & inhibitors
  • SRS-A / pharmacology

Substances

  • Bronchodilator Agents
  • NPPA protein, human
  • Peptide Fragments
  • SRS-A
  • anaritide
  • Atrial Natriuretic Factor